UPDATE 1-U.S. FDA panel to vote whether diabetes drug cuts cardiac death

UPDATE 1-U.S. FDA panel to vote whether diabetes drug cuts cardiac death

An advisory panel to the U.S. Food and Drug Administration will be asked to vote next week on whether a diabetes drug made by Eli Lilly & Co and Boehringer Ingelheim cuts the risk of cardiovascular death, according to documents posted on the agency's website on Friday. The documents were published ahead of a June 28 meeting of outside advisors who will discuss the drug, Jardiance, and recommend whether the label should include a claim that it cuts the risk of heart problems in patients at high risk.

from Biotech News